Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach-Reference-Cited by-同舟云学术

Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach

Published:2001-10 Issue:20 Volume:11 Page:2775-2778
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Smith Roger A,Barbosa James,Blum Cheri L,Bobko Mark A,Caringal Yolanda V,Dally Robert,Johnson Jeffrey S,Katz Michael E,Kennure Nancy,Kingery-Wood Jill,Lee Wendy,Lowinger Timothy B,Lyons John,Marsh Vivienne,Rogers Daniel H,Swartz Stephen,Walling Tracy,Wild Hanno

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference14 articles.

1. FUNCTION AND REGULATION OF RAS

2. The Role of Raf Kinases in Development and Growth of Tumors

3. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

4. The discovery of potent cRaf1 kinase inhibitors

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

3. Neuroblastoma and its Target Therapies: A Medicinal Chemistry Review;ChemMedChem;2024-03-26

4. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications;Drug Design, Development and Therapy;2024-03

5. p38 mitogen-activated protein kinase inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024